WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback